Zacks Investment Research cut shares of Intec Pharma (NASDAQ:NTEC) from a buy rating to a hold rating in a research note issued to investors on Wednesday.

According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “

A number of other equities research analysts have also recently issued reports on the stock. Oppenheimer set a $15.00 target price on shares of Intec Pharma and gave the company a buy rating in a research report on Monday, December 18th. Maxim Group set a $8.00 target price on shares of Intec Pharma and gave the company a buy rating in a research report on Friday, November 17th. ValuEngine cut shares of Intec Pharma from a hold rating to a sell rating in a research report on Thursday, November 16th. Finally, CIBC reissued an outperform rating and issued a $15.00 target price (up previously from $10.00) on shares of Intec Pharma in a research report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Intec Pharma currently has a consensus rating of Buy and an average price target of $11.15.

Shares of Intec Pharma (NTEC) opened at $7.05 on Wednesday. Intec Pharma has a 52-week low of $4.20 and a 52-week high of $9.80.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Pura Vida Investments LLC bought a new stake in Intec Pharma during the third quarter worth about $895,000. Sectoral Asset Management Inc bought a new stake in Intec Pharma during the third quarter worth about $3,177,000. Caxton Corp bought a new stake in Intec Pharma during the third quarter worth about $681,000. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its position in Intec Pharma by 5.0% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 522,200 shares of the biotechnology company’s stock worth $2,977,000 after purchasing an additional 25,000 shares during the period. 40.16% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Intec Pharma (NTEC) Downgraded by Zacks Investment Research” was first posted by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.watchlistnews.com/intec-pharma-ntec-downgraded-by-zacks-investment-research/1797345.html.

About Intec Pharma

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Get a free copy of the Zacks research report on Intec Pharma (NTEC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.